Research analysts at LADENBURG THALM/SH SH started coverage on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research note issued to investors on Wednesday, MarketBeat reports. The firm set a “buy” rating and a $9.00 price target on the stock. LADENBURG THALM/SH SH’s price target points to a potential upside of 411.36% from the stock’s current price.

A number of other analysts have also commented on the stock. ValuEngine upgraded shares of Outlook Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. CIBC assumed coverage on shares of Outlook Therapeutics in a report on Thursday, May 16th. They set an “outperform” rating and a $12.00 price objective on the stock. HC Wainwright assumed coverage on shares of Outlook Therapeutics in a report on Thursday, July 18th. They set a “buy” rating and a $8.00 price objective on the stock. Zacks Investment Research raised shares of Outlook Therapeutics from a “hold” rating to a “buy” rating and set a $1.75 price objective on the stock in a report on Tuesday. Finally, Oppenheimer assumed coverage on shares of Outlook Therapeutics in a report on Thursday, May 16th. They set an “outperform” rating and a $12.00 price objective on the stock. Seven equities research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $7.79.

Get Outlook Therapeutics alerts:

OTLK stock traded up $0.01 during midday trading on Wednesday, reaching $1.76. 65,894 shares of the company’s stock traded hands, compared to its average volume of 371,797. The company has a market cap of $49.71 million, a price-to-earnings ratio of -0.16 and a beta of -0.64. The firm’s fifty day moving average price is $1.89 and its 200-day moving average price is $2.41. Outlook Therapeutics has a 52 week low of $0.85 and a 52 week high of $10.96.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.24) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.13. The business had revenue of $0.58 million for the quarter, compared to the consensus estimate of $0.73 million. On average, equities research analysts anticipate that Outlook Therapeutics will post -2.08 earnings per share for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Chicago Capital LLC bought a new stake in shares of Outlook Therapeutics during the second quarter valued at about $40,000. Vanguard Group Inc. increased its position in shares of Outlook Therapeutics by 712.1% during the second quarter. Vanguard Group Inc. now owns 396,001 shares of the company’s stock valued at $824,000 after buying an additional 347,238 shares during the period. Finally, Cormorant Asset Management LP bought a new stake in shares of Outlook Therapeutics during the second quarter valued at about $32,000. Hedge funds and other institutional investors own 2.95% of the company’s stock.

About Outlook Therapeutics

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibody for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic bevacizumab product candidate that is in first clinical trial for the treatment of wet age related macular degeneration and other retina diseases.